FDA approves new nasal spray medication for treatment-resistant ...
The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have...
SPRAVATO® (esketamine): A Prescription Nasal Spray
1 day ago · SPRAVATO®, the only FDA-approved nasal spray for adult patients with two forms of challenging-to-treat major depressive disorder (MDD): Adults with MDD who’ve had an inadequate response to two or more oral antidepressants, known as treatment-resistant depression (TRD)
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Oct 4, 2023 · In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week...
Mayo Clinic Q and A: New treatment for hard-to-treat depression
Jul 12, 2019 · DEAR MAYO CLINIC: How is the new nasal spray for depression different than other drugs used to treat depression? How do doctors determine who is a good candidate for this new kind of antidepressant?
Managing Depression With Spravato - WebMD
Aug 15, 2024 · Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is approved for use with other antidepressant medicines that are taken by mouth. It is...
Esketamine for Treatment-Resistant Depression - Johns Hopkins Medicine
But it wasn’t until recently that esketamine, a more potent version of ketamine, earned FDA approval specifically for use as a nasal spray for those with treatment-resistant depression. Esketamine is derived from part of the ketamine molecule,” says …
J&J’s comeback kid Spravato heads for blockbuster status
Oct 25, 2024 · Johnson & Johnson’s esketamine nasal spray Spravato didn’t look like a sure-fire win after it hit the market in 2019. Despite blazing a new trail as the first psychedelic-based treatment to score an FDA nod, the depression medication got off to a sluggish start, and the company didn’t even report sales figures for the first few years.
Spravato is just the beginning in a new wave of depression meds
4 days ago · The esketamine-based nasal spray ultimately won FDA approval in 2019, delivering the depression space its first new medication in decades. Spravato also offered an option that could provide more rapid treatment than the four to six weeks selective serotonin reuptake inhibitors, depression’s go-to drugs, usually take to kick in.
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Oct 5, 2023 · In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).
Long-term safety and maintenance of response with esketamine nasal …
May 12, 2023 · Esketamine nasal spray (Spravato ®, Janssen Pharmaceuticals Inc., Titusville, NJ), in conjunction with a newly-initiated oral antidepressant, has been approved for TRD by the US Food and Drug...